Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Saturday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 11.1 %

Eagle Pharmaceuticals stock opened at $0.80 on Friday. The company has a 50 day moving average price of $0.68 and a 200-day moving average price of $2.17. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.81.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Mackenzie Financial Corp purchased a new position in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eagle Pharmaceuticals in the second quarter valued at $65,000. Creative Planning purchased a new position in shares of Eagle Pharmaceuticals during the third quarter valued at approximately $59,000. Cubist Systematic Strategies LLC purchased a new position in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $145,000. Finally, Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth about $96,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.